自己免疫性溶血性貧血治療薬の世界市場予測・分析2019-2023

◆英語タイトル:Autoimmune Hemolytic Anemia Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023
◆商品コード:IRTNTR32136
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年10月31日
◆ページ数:150
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、自己免疫性溶血性貧血治療薬の世界市場について調べ、自己免疫性溶血性貧血治療薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、自己免疫性溶血性貧血治療薬の市場規模をセグメンテーション別(製品別(コルチコステロイド、モノクローナル抗体、その他)、)と地域別(グローバル)に分けて算出しました。Technavio社は自己免疫性溶血性貧血治療薬の世界市場規模が2019-2023期間中に年平均9%成長すると予測しています。
・サマリー
・レポートの範囲
・自己免疫性溶血性貧血治療薬の市場状況
・自己免疫性溶血性貧血治療薬の市場規模
・自己免疫性溶血性貧血治療薬の市場予測
・自己免疫性溶血性貧血治療薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(コルチコステロイド、モノクローナル抗体、その他)
・自己免疫性溶血性貧血治療薬の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Autoimmune Hemolytic Anemia Therapeutics Market: About this market
Technavio’s autoimmune hemolytic anemia therapeutics market analysis considers sales from corticosteroids, monoclonal antibodies, and other products. Our analysis also considers the sales of autoimmune hemolytic anemia therapeutics in Asia, Europe, North America, and ROW. In 2018, the corticosteroids segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the strong therapeutic value of corticosteroids will play a significant role in the corticosteroids segment to maintain its market position. Also, our global autoimmune hemolytic anemia therapeutics market report looks at factors such as regulatory incentives, patient assistance programs, and adverse effects and complications associated with blood transfusion and splenectomy. However, lack of effective therapies, side-effects of drugs, and lack of specific diagnostic tests and awareness may hamper the growth of the autoimmune hemolytic anemia therapeutics industry over the forecast period.

Global Autoimmune Hemolytic Anemia Therapeutics Market: Overview
Patient Assistance Program
The high cost of therapeutics to treat autoimmune hemolytic anemia has encouraged pharmaceutical companies and governments of various countries to come up with financial assistance programs and reimbursements over the years. Financial assistance programs such as Obamacare in the US have minimized the treatment cost burden on patients. They help in providing the required medicines to patients and increase patient compliance to treatments including monoclonal antibodies such as rituximab. Such patient assistance program will lead to the expansion of the global autoimmune hemolytic anemia therapeutics market at a CAGR of over 9% during the forecast period.

R&D of Novel therapeutics
There is a limited number of drugs available for the treatment of autoimmune hemolytic anemia. This has driven the pharmaceutical companies and biotechnology researchers to invest in R&D activities to develop novel therapeutics such as fostamatinib and parsaclisib. These therapeutics are under development and have exhibited high efficacy and safety profile. This, in turn, will accelerate the approval of novel therapeutics for the treatment of autoimmune hemolytic anemia and have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global autoimmune hemolytic anemia therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global autoimmune hemolytic anemia therapeutics market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading autoimmune hemolytic anemia therapeutics manufacturers, that include Amneal Pharmaceuticals Inc., Baxter International Inc., F. Hoffmann-La Roche Ltd., Incyte Corp., Kezar Life Sciences Inc., Mylan NV, Pfizer Inc., Rigel Pharmaceuticals Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Also, the autoimmune hemolytic anemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Corticosteroids – Market size and forecast 2018-2023

Monoclonal antibodies – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

R&D of novel therapeutics

Advances in murine models

Development of combination therapies

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amneal Pharmaceuticals Inc.

Baxter International Inc.

F. Hoffmann-La Roche Ltd.

Incyte Corp.

Kezar Life Sciences Inc.

Mylan NV

Pfizer Inc.

Rigel Pharmaceuticals Inc.

Sanofi

Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Corticosteroids – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Corticosteroids – Year-over-year growth 2019-2023 (%)

Exhibit 22: Monoclonal antibodies – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Monoclonal antibodies – Year-over-year growth 2019-2023 (%)

Exhibit 24: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Others – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by product

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Impact of drivers and challenges

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: Amneal Pharmaceuticals Inc. – Vendor overview

Exhibit 51: Amneal Pharmaceuticals Inc. – Business segments

Exhibit 52: Amneal Pharmaceuticals Inc. – Organizational developments

Exhibit 53: Amneal Pharmaceuticals Inc. – Segment focus

Exhibit 54: Amneal Pharmaceuticals Inc. – Key offerings

Exhibit 55: Amneal Pharmaceuticals Inc. – Key customers

Exhibit 56: Baxter International Inc. – Vendor overview

Exhibit 57: Baxter International Inc. – Business segments

Exhibit 58: Baxter International Inc. – Organizational developments

Exhibit 59: Baxter International Inc. – Segment focus

Exhibit 60: Baxter International Inc. – Key offerings

Exhibit 61: Baxter International Inc. – Key customers

Exhibit 62: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 63: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 64: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 65: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 66: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 67: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 68: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 69: Incyte Corp. – Vendor overview

Exhibit 70: Incyte Corp. – Business segments

Exhibit 71: Incyte Corp. – Organizational developments

Exhibit 72: Incyte Corp. – Key offerings

Exhibit 73: Incyte Corp. – Key customers

Exhibit 74: Kezar Life Sciences Inc. – Vendor overview

Exhibit 75: Kezar Life Sciences Inc. – Business segments

Exhibit 76: Kezar Life Sciences Inc. – Organizational developments

Exhibit 77: Kezar Life Sciences Inc. – Key offerings

Exhibit 78: Kezar Life Sciences Inc. – Key customers

Exhibit 79: Mylan NV – Vendor overview

Exhibit 80: Mylan NV – Product segments

Exhibit 81: Mylan NV – Organizational developments

Exhibit 82: Mylan NV – Geographic focus

Exhibit 83: Mylan NV – Segment focus

Exhibit 84: Mylan NV – Key offerings

Exhibit 85: Mylan NV – Key customers

Exhibit 86: Pfizer Inc. – Vendor overview

Exhibit 87: Pfizer Inc. – Business segments

Exhibit 88: Pfizer Inc. – Organizational developments

Exhibit 89: Pfizer Inc. – Geographic focus

Exhibit 90: Pfizer Inc. – Segment focus

Exhibit 91: Pfizer Inc. – Key offerings

Exhibit 92: Pfizer Inc. – Key customers

Exhibit 93: Rigel Pharmaceuticals Inc. – Vendor overview

Exhibit 94: Rigel Pharmaceuticals Inc. – Business segments

Exhibit 95: Rigel Pharmaceuticals Inc. – Organizational developments

Exhibit 96: Rigel Pharmaceuticals Inc. – Key offerings

Exhibit 97: Rigel Pharmaceuticals Inc. – Key customers

Exhibit 98: Sanofi – Vendor overview

Exhibit 99: Sanofi – Business segments

Exhibit 100: Sanofi – Organizational developments

Exhibit 101: Sanofi – Geographic focus

Exhibit 102: Sanofi – Segment focus

Exhibit 103: Sanofi – Key offerings

Exhibit 104: Sanofi – Key customers

Exhibit 105: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 106: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 107: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 108: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 109: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 110: Teva Pharmaceutical Industries Ltd. – Key customers

Exhibit 111: Validation techniques employed for market sizing

Exhibit 112: Definition of market positioning of vendors



【掲載企業】

Amneal Pharmaceuticals Inc.
Baxter International Inc.
F. Hoffmann-La Roche Ltd.
Incyte Corp.
Kezar Life Sciences Inc.
Mylan NV
Pfizer Inc.
Rigel Pharmaceuticals Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[自己免疫性溶血性貧血治療薬の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆